{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:24:08Z","timestamp":1792020248158,"version":"4.4.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["20ZR1459500"],"award-info":[{"award-number":["20ZR1459500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173864"],"award-info":[{"award-number":["82173864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671745"],"award-info":[{"award-number":["81671745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671989"],"award-info":[{"award-number":["81671989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["18411951300"],"award-info":[{"award-number":["18411951300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    Recent decades have seen a significant increase in invasive fungal infections, resulting in unacceptably high mortality rates. Anidulafungin (AN) is the newest echinocandin and appears to have several advantages over existing antifungals. However, its poor water solubility and burdensome route of administration (i.e., repeated, long-term intravenous infusions) have limited its practical use. The objective of this study was to develop anidulafungin-loaded Human Serum Albumin (HSA) nanoparticles (NP) so as to increase both its solubility and antifungal efficacy. HSA was reduced using SDS and DTT, allowing liberation of free thiols to form the intermolecular disulfide network and nanoassembly. Reduced HSA was then added to MES buffer (0.1 M, pH 4.8) and magnetically stirred at 350 rpm and 25\u00b0C with AN (m\/m 50:1) for 2 h to form nanoparticles (AN NP). We next performed routine antifungal susceptibility testing of\n                    <jats:italic>Candida<\/jats:italic>\n                    strains (\n                    <jats:italic>n<\/jats:italic>\n                    = 31) using Clinical and Laboratory Standards Institute (CLSI) methodologies. Finally, the\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy of both AN and AN NP was investigated in a murine model of invasive infection by one of the most common fungal species\u2014\n                    <jats:italic>C. albicans.<\/jats:italic>\n                    The results indicated that our carrier formulations successfully improved the water solubility of AN and encapsulated AN, with the latter having a particle size of 29 \u00b1 1.5 nm with Polymer dispersity index (PDI) equaling 0.173 \u00b1 0.039.\n                    <jats:italic>In vitro<\/jats:italic>\n                    AN NP testing revealed a stronger effect against\n                    <jats:italic>Candida<\/jats:italic>\n                    species (\n                    <jats:italic>n<\/jats:italic>\n                    = 31), with Minimum Inhibitory Concentration (MIC) values 4- to 32-fold lower than AN alone. In mice infected with\n                    <jats:italic>Candida<\/jats:italic>\n                    and having invasive candidiasis, we found that AN NP prolonged survival time (\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.005) and reduced fungal burden in kidneys compared to equivalent concentrations of free drug (\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.0001). In conclusion, the anidulafungin nanoparticles developed here have the potential to improve drug administration and therapeutic outcomes for individuals suffering from fungal diseases.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2021.788442","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:12:52Z","timestamp":1639462372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the in vitro Activity and in vivo Efficacy of Anidulafungin-Loaded Human Serum Albumin Nanoparticles Against Candida albicans"],"prefix":"10.3389","volume":"12","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Tong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Ran","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Mao","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections.","volume":"4","author":"Brown","year":"","journal-title":"Sci. Transl. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1126\/science.1222236","article-title":"Tackling human fungal infections.","volume":"336","author":"Brown","year":"","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcp.2016.11.019","article-title":"Antifungals.","volume":"133","author":"Campoy","year":"2017","journal-title":"Biochem. Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis.","volume":"26","author":"Denning","year":"1998","journal-title":"Clin. Infect Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"Infectious disease. how to bolster the antifungal pipeline.","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijpharm.2007.03.036","article-title":"Preparation, characterisation and maintenance of drug efficacy of doxorubicin-Loaded human serum albumin (HSA) nanoparticles.","volume":"341","author":"Dreis","year":"2007","journal-title":"Int. J. Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ijbiomac.2019.07.096","article-title":"Recent developments in the detection of Bovine serum albumin.","volume":"138","author":"Jahanban-Esfahlan","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","article-title":"Albumin nanostructures as advanced drug delivery Systems.","volume":"13","author":"Karimi","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and Nanoparticles.","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control Release"},{"key":"B10","first-page":"217","article-title":"Evaluation of nanoparticles as drug-delivery systems. II: Comparison of the body distribution of nanoparticles with the body distribution of Microspheres (diameter greater than 1 micron), liposomes, and emulsions.","volume":"58","author":"Kreuter","year":"1983","journal-title":"Pharm. Acta Helv."},{"key":"B11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1592\/phco.29.1.17","article-title":"Pharmacology and antifungal properties of anidulafungin, a new echinocandin.","volume":"29","author":"Kristina","year":"2009","journal-title":"Pharmacotherapy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jconrel.2020.05.026","article-title":"Turning Weakness into strength: Albumin nanoparticle-redirected amphotericin B Biodistribution for reducing nephrotoxicity and enhancing antifungal activity.","volume":"324","author":"Liu","year":"2020","journal-title":"J. Control Release."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2165\/00003495-200464190-00011","article-title":"Anidulafungin.","volume":"64","author":"Murdoch","year":"2004","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1758834016639873","article-title":"Targeted chemotherapy with Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: Which benefit for which patients?","volume":"8","author":"Palumbo","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/01.aog.0000239499.97978.bc","article-title":"Anidulafungin (Eraxis) for Candida infections.","volume":"48","author":"Patel","year":"2006","journal-title":"Med. Lett. Drugs Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1358\/dot.2006.42.9.1009902","article-title":"Nanoparticle albumin-bound paclitaxel for Treatment of metastatic breast cancer.","volume":"42","author":"Pinder","year":"2006","journal-title":"Drugs Today"},{"key":"B17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12938-019-0624-7","article-title":"Docetaxel-loaded human Serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation.","volume":"18","author":"Qu","year":"2019","journal-title":"Biomed. Eng. Online"},{"key":"B18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1023\/a:1015852732512","article-title":"Phagocytosis of nanoparticles by human immunodeficiency virus (hlv)-infected macrophages: a possibility for antiviral drug targeting.","volume":"9","author":"Sch\u00e4fer","year":"1992","journal-title":"Pharm. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: a novel echinocandin.","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin. Infect. Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/jbm.a.36984","article-title":"Anidulafungin liposome Nanoparticles exhibit antifungal activity against planktonic and biofilm Candida Albicans.","volume":"108","author":"Vera-Gonz\u00e1lez","year":"2020","journal-title":"J. Biomed. Mater Res. A"},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0378-5173(99)00420-2","article-title":"Desolvation process and surface Characteristics of HSA-nanoparticles.","volume":"196","author":"Weber","year":"2000","journal-title":"Int. J. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/2047-783x-16-4-180","article-title":"Treatment and prophylaxis of invasive candidiasis with Anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature.","volume":"16","author":"Wilke","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery.","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control Release"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.788442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:12:57Z","timestamp":1639462377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.788442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":23,"alternative-id":["10.3389\/fmicb.2021.788442"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.788442","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"article-number":"788442"}}